{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T11:34:39Z","timestamp":1769945679356,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.soncn.2021.151173","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T01:30:52Z","timestamp":1627608652000},"page":"151173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Multidisciplinary Professional Roles Addressing Needs in Multiple Myeloma: An Innovative \u2018Virtual\u2019 Pharmacist Surveillance Clinic"],"prefix":"10.1016","volume":"37","author":[{"given":"Marina","family":"Ebied","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.soncn.2021.151173_bib0001","unstructured":"Canadian Cancer Society. Multiple myeloma statistics. Available at: https:\/\/www.cancer.ca\/en\/cancer-information\/cancer-type\/multiple-myeloma\/statistics\/?region=ab. Accessed April 26, 2021."},{"key":"10.1016\/j.soncn.2021.151173_bib0002","unstructured":"Alberta Health Services. Multiple myeloma clinical practice guideline LYHE-003. Available at:: https:\/\/www.albertahealthservices.ca\/assets\/info\/hp\/cancer\/if-hp-cancer-guide-lyhe003-multi-myeloma.pdf. Accessed month day, year."},{"key":"10.1016\/j.soncn.2021.151173_bib0003","unstructured":"Castillo J, Aird W, Lonial S. Multiple myeloma.Available at: https:\/\/www-dynamed-com.ahs.idm.oclc.org\/condition\/multiple-myeloma#INCIDENCE_PREVALENCE. Accessed May 13, 2021"},{"key":"10.1016\/j.soncn.2021.151173_bib0004","unstructured":"Canadian Cancer Society. Multiple myeloma prognosis and survival for multiple myeloma. Available at: https:\/\/www.cancer.ca\/en\/cancer-information\/cancer-type\/multiple-myeloma\/prognosis-and-survival\/?region=ab. Accessed April 26, 2020."},{"key":"10.1016\/j.soncn.2021.151173_bib0005","unstructured":"National Comprehensive Cancer Network. Multiple myeloma. Available at: www.nccn.org. Accessed April 26, 2021."},{"key":"10.1016\/j.soncn.2021.151173_bib0006","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.soncn.2021.151173_bib0007","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1200\/JOP.18.00085","article-title":"Collaborative physician-pharmacist\u2013managed multiple myeloma clinic improves guideline adherence and prevents treatment delays","volume":"14","author":"Sweiss","year":"2018","journal-title":"J Oncol Pract"},{"issue":"31","key":"10.1016\/j.soncn.2021.151173_bib0008","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.soncn.2021.151173_bib0009","unstructured":"Lexicomp. Lexicomp (Lexi-Drugs). Available at: http:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/patch_f\/5928764?cesid=8sUTsuP2dje&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Ddaratumumab%26t%3Dname%26va%3Ddaratumumab#rfs. Accessed April 26, 2021."},{"issue":"1","key":"10.1016\/j.soncn.2021.151173_bib0010","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/1078155211402104","article-title":"Optimizing pain relief in a specialized outpatient palliative radiotherapy clinic: contributions of a clinical pharmacist","volume":"18","author":"Gagnon","year":"2012","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"10.1016\/j.soncn.2021.151173_bib0011","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijrobp.2009.07.1698","article-title":"Multidisciplinary team contributions within a dedicated outpatient palliative radiotherapy clinic: a prospective descriptive study","volume":"78","author":"Pituskin","year":"2010","journal-title":"Int J Radiat Oncol Biol Physics"},{"issue":"11","key":"10.1016\/j.soncn.2021.151173_bib0012","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1200\/JOP.2016.013912","article-title":"Supporting patients with incurable cancer: backup behavior in multidisciplinary cross-functional teams","volume":"12","author":"Huang","year":"2016","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.soncn.2021.151173_bib0013","unstructured":"Alberta Health Services. Workload reporting for clinically deployed staff. Available at: https:\/\/share.ahsnet.ca\/teams\/PSPP\/PCP\/ClinicalPractice\/Clinical%20Workload%20Reporting\/Workload%20Reporting%20Activities.pdf. Accessed month day, year."},{"key":"10.1016\/j.soncn.2021.151173_bib0014","unstructured":"Alberta College of Pharmacy. Additional prescribing authority. Available at: https:\/\/abpharmacy.ca\/sites\/default\/files\/HPGuidePrescribing.pdf. Accessed month day, year."},{"key":"10.1016\/j.soncn.2021.151173_bib0015","unstructured":"Alberta College of Pharmacy. Additional prescribing authority. Available at: https:\/\/abpharmacy.ca\/sites\/default\/files\/APA_Algorithm.pdf. Accessed month day, year."},{"issue":"4","key":"10.1016\/j.soncn.2021.151173_bib0016","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.clml.2013.03.006","article-title":"Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis","volume":"13","author":"Nardone","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.soncn.2021.151173_bib0017","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","article-title":"Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network","volume":"32","author":"Ludwig","year":"2018","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.soncn.2021.151173_bib0018","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.soncn.2021.151173_bib0019","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.soncn.2021.151173_bib0020","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.soncn.2021.151173_bib0021","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.soncn.2021.151173_bib0022","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.soncn.2021.151173_bib0023","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.soncn.2021.151173_bib0024","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1002\/cam4.2253","article-title":"Response to pneumococcal vaccination in multiple myeloma","volume":"8","author":"Renaud","year":"2019","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.soncn.2021.151173_bib0025","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00277-019-03621-1","article-title":"The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey","volume":"98","author":"Brioli","year":"2019","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.soncn.2021.151173_bib0026","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208121000644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208121000644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:36:07Z","timestamp":1760081767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208121000644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0749208121000644"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2021.151173","relation":{},"ISSN":["0749-2081"],"issn-type":[{"value":"0749-2081","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multidisciplinary Professional Roles Addressing Needs in Multiple Myeloma: An Innovative \u2018Virtual\u2019 Pharmacist Surveillance Clinic","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2021.151173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151173"}}